Biosimilar Development News

  1. Sandoz Announces Global Deal To Commercialize Proposed Biosimilar Natalizumab, A Key Multiple Sclerosis Medicine

    Sandoz, a Novartis division and a global leader in biosimilars, today announced that it has entered into a global commercialization agreement for a proposed natalizumab biosimilar. The medicine is in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS).

  2. Polpharma Biologics Announces Global Commercialization Deal For Biosimilar Natalizumab, A Key Multiple Sclerosis Medicine

    Polpharma Biologics S.A. ("Polpharma Biologics") today announces that it has entered a global commercialization agreement with Sandoz AG for a natalizumab biosimilar.

  3. Cancer Drugs Now Account For 27% Of All New Drug Approvals In The U.S., According To Tufts Center For The Study Of Drug Development

    Cancer drugs currently account for 27% of all new drug approvals in the United States since 2010, a dramatic increase from the 4% share of the 1980s, a newly completed analysis from the Tufts Center for the Study of Drug Development shows.

  4. Biosimilars And JAK Inhibitors Continue To Gain Popularity In The EU Rheumatoid Arthritis Market, According To Spherix Global Insights

    Twice a year, Spherix collects the responses of ~250 EU5 rheumatologists as part of their RealTime Dynamix™: Rheumatoid Arthritis (EU) service. This study, which includes trending back to 2017 as well as unique content with each wave, reveals ongoing changes in treatment preferences and the growing importance of newer advanced systemic agents.

  5. Innovent Biologics Study Results Of IBI303 In Patients With Ankylosing Spondylitis Was Published In ‘The Lancet Rheumatology’

    Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the clinical trial results of IBI303, an anti-tumor necrosis factor-alpha (anti-TNF-alpha) monoclonal antibody injection developed by Innovent, has been published in The Lancet Rheumatology, a leading international medical journal, with comment by Stanley Cohen, professor of University of Texas Southwestern Medical Center.

  6. Alvotech And Prestige Biopharma Announce New Manufacturing Partnership

    Alvotech and Prestige Biopharma, recently announced a new contract manufacturing partnership for one of Prestige Biopharma´s biosimilar candidates. 

  7. iBio And CC-Pharming Expand Business Collaboration In China

    iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has expanded the scope of its business venture with CC-Pharming Ltd. by granting it an exclusive, royalty-bearing commercial license to iBio’s bio-better rituximab (“iBio Rituximab”) product candidates for the territory of China. In addition, the Company will grant to CC-Pharming a research license to iBio’s FastPharming System and know-how for the evaluation of multiple product opportunities.

  8. Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)

    Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798, a biosimilar candidate to Rituxan® (rituximab), compared to Rituxan in patients with CD20-positive B-cell non-Hodgkin's lymphoma.

  9. New Analysis Encourages Employer Engagement To Help Realize Significant Savings Potential Of Biosimilars

    Employers have a vital role to play in promoting biosimilars utilization, a new analysis found, pointing to significant savings potentials if employers make concerted efforts to provide incentives for and increase education of biosimilar use with physicians and patients.

  10. STADA: Teriparatide-Biosimilar Movymia For Treatment Of Osteoporosis Launched In 24 Countries

    On time for patent expiration of the reference product Forsteo, STADA is gradually launching the biosimilar Movymia as a cost-effective alternative in 24 countries starting at the end of August. Forsteo had a sales volume of almost EUR 250 million over the last 12 months in Europe. Teriparatide is approved for the treatment of osteoporosis and is the only active ingredient approved for osteoanabolic therapy.